Cargando…

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

The RV144 vaccine trial showed reduced risk of HIV-1 acquisition by 31.2%, although mechanisms that led to protection remain poorly understood. Here we identify transcriptional correlates for reduced HIV-1 acquisition after vaccination. We assess the transcriptomic profile of blood collected from 22...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fourati, Slim, Ribeiro, Susan Pereira, Blasco Tavares Pereira Lopes, Filipa, Talla, Aarthi, Lefebvre, Francois, Cameron, Mark, Kaewkungwal, J., Pitisuttithum, P., Nitayaphan, S., Rerks-Ngarm, S., Kim, Jerome H., Thomas, Rasmi, Gilbert, Peter B., Tomaras, Georgia D., Koup, Richard A., Michael, Nelson L., McElrath, M. Juliana, Gottardo, Raphael, Sékaly, Rafick-Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382801/ https://www.ncbi.nlm.nih.gov/pubmed/30787294 http://dx.doi.org/10.1038/s41467-019-08854-2

Ejemplares similares

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
por: Choi, Ickwon, et al.
Publicado: (2015)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
por: Fischinger, Stephanie, et al.
Publicado: (2020)

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
por: McLellan, JS, et al.
Publicado: (2012)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
por: Nicely, Nathan I., et al.
Publicado: (2015)

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
por: Edlefsen, Paul T., et al.
Publicado: (2015)

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144
por: Perez, Lautaro G., et al.
Publicado: (2017)

RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
por: Lewitus, Eric, et al.
Publicado: (2021)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012)

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial
por: Hertz, T, et al.
Publicado: (2012)

RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2020)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2021)

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants
por: Dommaraju, Kalpana, et al.
Publicado: (2014)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
por: Shangguan, Shida, et al.
Publicado: (2021)

RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues
por: Liyanage, NP, et al.
Publicado: (2012)

Fcgbp – A Potential Viral Trap in RV144
por: Schwartz, Jacquelyn L
Publicado: (2014)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
por: Shubin, Zhanna, et al.
Publicado: (2023)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
por: Easterhoff, David, et al.
Publicado: (2017)

Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation
por: Pandiyan, Pushpa, et al.
Publicado: (2016)

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor
por: Peachman, Kristina K., et al.
Publicado: (2015)

Molecular epidemiology of the protective RV144 V2 loop epitope
por: Cardozo, T
Publicado: (2012)

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination
por: Fourati, Slim, et al.
Publicado: (2016)

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
por: Bonsignori, M, et al.
Publicado: (2012)

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
por: Janes, Holly, et al.
Publicado: (2015)

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes
por: Pollara, J, et al.
Publicado: (2012)

Aggregate complexes of HIV-1 induced by multimeric antibodies
por: Stieh, Daniel J, et al.
Publicado: (2014)

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection
por: Wang, Yufei, et al.
Publicado: (2017)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
por: Kim, JH, et al.
Publicado: (2009)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
por: Pitisuttithum, Punnee, et al.
Publicado: (2013)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
por: Yu, B, et al.
Publicado: (2012)

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4(+) T Cells
por: Kulpa, Deanna A., et al.
Publicado: (2019)

Correction: Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
Publicado: (2016)

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
por: Tomalka, Jeffrey Alan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bfaj4kuho6r6pnhavbn6luvvao